tiprankstipranks
Trending News
More News >

Shanghai Pharmaceuticals Subsidiary Penalized for Anti-Monopoly Violations

Story Highlights

An announcement from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) is now available.

Shanghai Pharmaceuticals Holding Co., Ltd. announced that its subsidiary, Shanghai Sine United Medicinal Herbs Co., Ltd., received an administrative penalty from the Shanghai Municipal Administration for Market Regulation for violating anti-monopoly laws. The penalty includes a fine and forfeiture of illegal income, but the financial impact on the parent company is limited due to the subsidiary’s small contribution to overall revenue. The company has taken steps to enhance compliance and prevent future monopolistic behavior, reflecting its commitment to fair market practices and sustainable development.

More about Shanghai Pharmaceuticals Holding Co

Shanghai Pharmaceuticals Holding Co., Ltd. is a major player in the pharmaceutical industry in China, focusing on the production and distribution of medicinal products. It operates through a network of subsidiaries, with a market focus on both domestic and international pharmaceutical markets.

YTD Price Performance: -3.99%

Average Trading Volume: 29,934

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $7.91B

Find detailed analytics on 2607 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App